Co-Authors
This is a "connection" page, showing publications co-authored by Melissa Merritt and Danja Sarink.
Connection Strength
3.585
-
Sarink D, White KK, Loo LWM, Wu AH, Wilkens LR, Le Marchand L, Park SY, Setiawan VW, Merritt MA. Racial/ethnic differences in postmenopausal breast cancer risk by hormone receptor status: The multiethnic cohort study. Int J Cancer. 2022 01 15; 150(2):221-231.
Score: 0.815
-
Sarink D, Franke AA, White KK, Wu AH, Cheng I, Quon B, Le Marchand L, Wilkens LR, Yu H, Merritt MA. BPA, Parabens, and Phthalates in Relation to Endometrial Cancer Risk: A Case-Control Study Nested in the Multiethnic Cohort. Environ Health Perspect. 2021 05; 129(5):57702.
Score: 0.795
-
Sarink D, Wilkens LR, White KK, Le Marchand L, Wu AH, Setiawan VW, Park SL, Park SY, Killeen JL, Merritt MA. Racial/ethnic differences in anthropometric and hormone-related factors and endometrial cancer risk: the Multiethnic Cohort Study. Br J Cancer. 2021 05; 124(10):1724-1733.
Score: 0.787
-
Sarink D, Wu AH, Le Marchand L, White KK, Park SY, Setiawan VW, Hernandez BY, Wilkens LR, Merritt MA. Racial/Ethnic Differences in Ovarian Cancer Risk: Results from the Multiethnic Cohort Study. Cancer Epidemiol Biomarkers Prev. 2020 10; 29(10):2019-2025.
Score: 0.754
-
Meagher NS, White KK, Wilkens LR, Bandera EV, Berchuck A, Carney ME, Cramer DW, Cushing-Haugen KL, Jordan S, Kaufmann SH, Le ND, Pike MC, Riggan M, Qin B, Rothstein JH, Titus L, Winham SJ, Anton-Culver H, Doherty JA, Goode EL, Pearce CL, Risch HA, Aocs Group OBOT, Webb PM, Cook LS, Goodman MT, Harris HR, Le Marchand L, McGuire V, Pharoah PDP, Sarink D, Schildkraut JM, Sieh W, Terry KL, Thompson PJ, Whittemore AS, Wu AH, Peres LC, Merritt MA. Racial and ethnic differences in epithelial ovarian cancer risk: an analysis from the Ovarian Cancer Association Consortium. Am J Epidemiol. 2024 May 21.
Score: 0.245
-
Sarink D, Schock H, Johnson T, Overvad K, Holm M, Tj?nneland A, Boutron-Ruault MC, His M, Kvaskoff M, Boeing H, Lagiou P, Papatesta EM, Trichopoulou A, Palli D, Pala V, Mattiello A, Tumino R, Sacerdote C, Bueno-de-Mesquita HBA, van Gils CH, Peeters PH, Weiderpass E, Agudo A, S?nchez MJ, Chirlaque MD, Ardanaz E, Amiano P, Khaw KT, Travis R, Dossus L, Gunter M, Rinaldi S, Merritt M, Riboli E, Kaaks R, Fortner RT. Circulating RANKL and RANKL/OPG and Breast Cancer Risk by ER and PR Subtype: Results from the EPIC Cohort. Cancer Prev Res (Phila). 2017 Sep; 10(9):525-534.
Score: 0.153
-
Fortner RT, Sarink D, Schock H, Johnson T, Tj?nneland A, Olsen A, Overvad K, Affret A, His M, Boutron-Ruault MC, Boeing H, Trichopoulou A, Naska A, Orfanos P, Palli D, Sieri S, Mattiello A, Tumino R, Ricceri F, Bueno-de-Mesquita HB, Peeters PH, Van Gils CH, Weiderpass E, Lund E, Quir?s JR, Agudo A, S?nchez MJ, Chirlaque MD, Ardanaz E, Dorronsoro M, Key T, Khaw KT, Rinaldi S, Dossus L, Gunter M, Merritt MA, Riboli E, Kaaks R. Osteoprotegerin and breast cancer risk by hormone receptor subtype: a nested case-control study in the EPIC cohort. BMC Med. 2017 02 08; 15(1):26.
Score: 0.037